<DOC>
	<DOCNO>NCT00709826</DOCNO>
	<brief_summary>This study compare anti-tumor efficacy apricoxib gemcitabine/erlotinib placebo gemcitabine/erlotinib patient advance pancreatic cancer .</brief_summary>
	<brief_title>APRiCOT-P : Study Apricoxib With Gemcitabine Erlotinib Treat Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This study compare anti-tumor efficacy apricoxib gemcitabine/erlotinib placebo gemcitabine/erlotinib measure progression-free survival test hypothesis regulation COX-2 EGFR pathways patient up-regulated COX-2 expression tumor clinical benefit compare Gemcitabine/Erlotinib .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma pancreas locally advance metastatic . 2 . Life expectancy great equal 3 month . 3 . Patients must measurable disease RECIST . 4 . ECOG PS 0 , 1 , 2 . 5 . Negative serum pregnancy test time first dose woman childbearing potential . 1 . Previous chemotherapy primary treatment locally advance metastatic pancreatic cancer ( stage 3 T3 T4 , stage 4 ) . 2 . RT within 2 week chemotherapy within 3 week noncytotoxic investigational agent within 4 week initiate study treatment . 3 . Evidence New York Heart Association class III great cardiac disease . 4 . History myocardial infarction , stroke , ventricular arrhythmia . 5 . Symptomatic central nervous system metastasis . 6 . Pregnant nursing woman . 7 . Hypersensitivity intolerance apricoxib , erlotinib , gemcitabine , sulfonamide , aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) . 8 . History upper gastrointestinal bleeding , ulceration perforation . History low GI bleeding , ulceration , perforation within 12 month . 9 . Previous antiEGFR kinase therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>